📄 Direct examination of Collin Yamauchi (part 6) — Wednesday, May 24, 1995
Address:
C:\DEPT103\CRIMINAL\1995\MAY\24\DIRECT-EXAMINATION-OF-COLLIN-Y.DOC
TRIAL
▲ Day 81 of 167

Direct examination of Collin Yamauchi (part 6)

Witness: Collin Yamauchi
Examiner: Rockne Harmon
Called by: Prosecution • Date: Wednesday, May 24, 1995 • Utterances: 197
Rockne Harmon walks Collin Yamauchi through the LAPD's PCR DQ-Alpha testing procedure step by step, covering extraction at Piper Tech, amplification and hybridization at Parker Center, and electrophoresis back at Piper Tech. The testimony is highly technical and methodical, establishing the procedural chain and contamination-prevention measures used in analyzing evidence from the Simpson case. Barry Scheck lodges repeated objections for leading, most of which are overruled.
1 MR. HARMON:

Thank you, your Honor.

2 MR. HARMON:

Mr. Yamauchi, you had mentioned that the next tube in order was the cloth control. Can you explain to the jury what the function of the cloth control is in the PCR DQ-Alpha processing?

3 MR. YAMAUCHI:

It acts as a negative control in the analytical process for that particular step. From that point on, it would show us whether something funny happened or not.

4 MR. HARMON:

When you say "Show us whether something funny happened," can you give us an idea what you mean by that?

5 MR. YAMAUCHI:

Well, it's kind of inherent in the way I described that. By negative control, we expect it to come up negative. But if it comes up and it shows that there's some activity or something there, then it's quite possible some of our solutions at that point could have been contaminated. And this would be a way that we can double-check and know later on if something was astray or different that--at this point, a contaminant was present.

6 MR. HARMON:

And how would that tell you if any of those things happened, that control?

7 MR. YAMAUCHI:

That control? Like I was saying before, generally speaking, we expect it to be negative. But if some activity comes up throughout the whole process where we see something on a strip, then we know that perhaps something happened at that stage and it would help us and aid us in troubleshooting.

8 MR. HARMON:

When you say "See something on a strip," you mean a typing result?

9 MR. YAMAUCHI:

Yes.

10 MR. HARMON:

And what about the next control in order after the cloth control on this first set of DQ-Alpha typing? What was that after the cloth control?

11 MR. YAMAUCHI:

On my extraction sheet, there's nothing else after the cloth control.

12 MR. HARMON:

Okay. I believe at some later point, you also had amplification controls?

13 MR. YAMAUCHI:

Yes. That's correct.

14 MR. SCHECK:

Objection. Leading.

15 THE COURT:

Overruled.

16 MR. HARMON:

Your Honor, at this point, I would like to have marked as People's 281 for identification a photo display board, the LAPD PCR typing board.

17 THE COURT:

All right. 281.

18 (Peo's 281 for id = display board)
19 MR. HARMON:

Okay. Mr. Yamauchi, you've generally described the extraction procedure that you utilized in this case. And referring to People's 281 for identification, could you step down and, using the pointer, could you please describe what's shown in the photographs starting at the top horizontal strip that we've boxed in? It's entitled "Piper tech extraction." Now, the jury has heard what piper tech is, but you mentioned that the extraction is in the serology room?

20 MR. YAMAUCHI:

Serology, yes.

21 MR. HARMON:

Okay. And in the left-hand photo under "Piper tech extraction," could you explain what you are doing in that photograph?

22 MR. YAMAUCHI:

Okay. At this point right here, the first step is to add one unknown of sterile water. And that's to get out some extraneous components that may or may not be a problem. And one case in point would be the particular group that's labeled "Blood, red." There's no inhibitor of PCR process. So at this point here, by adding the water, it puts that group into the inclusion and it can later be separated from the DNA that were actually after.

23 MR. HARMON:

Mr. Yamauchi, could you try to keep your voice up because you've got your back to the Court reporter. I know it's important that we all get to hear you, okay? Okay. What's in the next photograph, the middle photograph, under pipe tech extraction?

24 MR. YAMAUCHI:

I believe I'm actually putting the water into the tube at that point.

25 MR. HARMON:

And is that the same tube that you started out by putting the cuttings that you made over in the evidence processing room there or is that a different one?

26 MR. YAMAUCHI:

Yes. That would be what's going on there.

27 MR. HARMON:

Okay. And then over in the right-hand side, what is that that you're doing and what is that machine?

28 MR. YAMAUCHI:

Oh, okay. After the water is placed into the tubes and allowed to soak for a--about 20 minutes or so, it's then put into the--what's called centrifuge--microcentrifuge--microcentrifuge tubes. This is what I'm doing. Goes into that instrument and spins it down at a high volume. All the solid components or heavy components like DNA, for example, are going to be forced towards the bottom while the other components that are in solution will just remain in solution.

29 MR. HARMON:

Okay. Now, what do you do with these tubes that are--after they've been centrifuged at the end of the process?

30 MR. YAMAUCHI:

At this point, there's another step called--it's kind of a mixture of chemical called chelex and it acts in a specific function in the extraction process which--and this is kind of weird because they're not really sure what its actual action is, but they do know that it does aid in taking out a component that could help in the degradation of DNA. So to a certain extent, it acts as kind of preservative.

31 MR. HARMON:

Now, are there different forms of extraction processes that one can do in order to do the PCR DQ-Alpha typing?

32 MR. YAMAUCHI:

Chelex is the one we use at our lab or the one that I use in this case. There's also what's known as a pheno chloroform extraction.

33 MR. HARMON:

Is that what's known as organic extraction?

34 MR. YAMAUCHI:

Yes.

35 MR. HARMON:

Okay. Now, are you familiar with the amplitype user guide for PCR DQ-Alpha typing that's provided by the manufacturer?

36 MR. YAMAUCHI:

Yes.

37 MR. HARMON:

Are both of those extraction processes described in the user guide?

38 MR. YAMAUCHI:

Yes, they are.

39 MR. HARMON:

Why did you do the chelex extraction procedure in this case?

40 MR. YAMAUCHI:

Well, generally speaking, that's the procedure that we use or I use personally most often, and that would be one reason. The other reason would be that it actually has lesser steps and it is faster.

41 MR. HARMON:

Okay. And do you process the evidence--or strike that. When you perform the extraction process, is it your practice to never open more than one tube at a time?

42 MR. SCHECK:

Objection. Leading.

43 THE COURT:

Sustained. Rephrase the question.

44 MR. SCHECK:

He asked the same question. He always does that.

KEY QUOTE
45 THE COURT:

Speaking objection, counsel.

46 MR. SCHECK:

I apologize.

47 MR. HARMON:

Mr. Yamauchi, how many tubes do you open at any given time during the extraction process?

48 MR. YAMAUCHI:

The same number goes for this process, one tube at a time.

49 MR. HARMON:

Is that something you would adhere to through the whole PCR DQ-Alpha process?

50 MR. SCHECK:

Objection. Leading.

51 THE COURT:

Overruled.

52 MR. YAMAUCHI:

Yes.

53 MR. HARMON:

Same reasons you described in the beginning?

54 MR. SCHECK:

Objection. Leading.

55 THE COURT:

Overruled.

56 MR. YAMAUCHI:

Yes.

57 MR. HARMON:

Now, is--could you describe how long the chelex extraction process takes in comparison with the organic extraction process?

58 MR. YAMAUCHI:

Well, I haven't done the organic one in a while, so I would have to reference that to get a time frame on it. But as far as the chelex is concerned for bloodstains, it's in an hour and a half about you can get the extraction completed.

59 MR. HARMON:

And is that the normal amount of time that it usually takes you?

60 MR. SCHECK:

Objection. Leading.

61 THE COURT:

Sustained.

62 MR. HARMON:

How long does it usually take you to perform the chelex extraction process in other cases?

63 MR. SCHECK:

Objection. Vague with respect to similar.

64 THE COURT:

Overruled.

65 MR. YAMAUCHI:

Yes. An hour and a half.

66 MR. HARMON:

Now, at the end of the extraction procedure, where do all the tubes end up?

67 MR. YAMAUCHI:

They would have been done in that same rack closed off.

68 MR. HARMON:

How do they get from the centrifuge to the rack?

69 MR. YAMAUCHI:

Well, I take them out.

70 MR. HARMON:

And then what do you do after you put them in a rack?

71 MR. YAMAUCHI:

After they're put in a rack, see, the next step would be amplification. So that rack of tubes would have to go over to where we have our thermal cycler, and that's the machine we use to do the amplification. We have that setup in our laboratory over at Parker Center facility. So there's a space difference of about a couple miles maybe or so, hop in the car and drive over there.

72 MR. HARMON:

Now, are you familiar with the provisions in the amplitype user guide with respect to the relationship of the amplification room to other work areas in the PCR DQ-Alpha process recommendations?

73 MR. YAMAUCHI:

The recommendations, safety precautions, they want all these rooms basically separated off in space and especially the amplification room and extraction and examination areas.

74 MR. HARMON:

Why is that?

75 MR. YAMAUCHI:

To eliminate the chances of cross-contamination. Especially of interest at this point is, when you're dealing with the amplification area, there is a second type of contaminant called the--well, you've probably heard this already--PCR carry-over. It's where part of the PCR process is more likely to contamination because of its perfect size and sequence. It's more likely to be a harmful contaminant. That's why we take extra precautions to keep this area physically out of the way of the other areas where we do our extractions and our evidence analyzing.

76 MR. HARMON:

And yours is pretty separate then?

77 MR. YAMAUCHI:

Yes. In our case, it is.

78 MR. HARMON:

Are you aware of any other laboratory that has those two rooms so far apart?

79 MR. SCHECK:

Objection. No foundation.

80 THE COURT:

Overruled.

81 MR. YAMAUCHI:

No.

82 MR. HARMON:

How do you get from piper tech serology to Parker Center? How did you get there on June 14th in this case?

83 MR. YAMAUCHI:

Via car.

84 MR. HARMON:

And government car?

85 MR. YAMAUCHI:

Yeah. City car.

86 MR. HARMON:

Will you describe how you transported the rack with the tubes?

87 MR. YAMAUCHI:

Well, the closed-off tubes are in the rack. And then one of those chem-wipes I described earlier, there's larger versions, I'll wrap that whole rack and everything up in the chem-wipe and transport it that way.

88 MR. HARMON:

Why did you put the chem-wipe on?

89 MR. YAMAUCHI:

Mostly because when you're walking along around the police station, it makes the detectives and people over there kind of nervous if they see little test-tube things. So I just want to make sure it's covered up.

KEY QUOTE
90 MR. HARMON:

Can you describe the facility or the rooms that you have over there? Are they normally staffed by anybody?

91 THE COURT:

Over where?

92 MR. HARMON:

At Parker Center.

93 MR. YAMAUCHI:

At Parker Center, it would just be the DNA people.

94 MR. HARMON:

And is there somebody whose assignment it is to be there all the time?

95 MR. YAMAUCHI:

No.

96 MR. HARMON:

How is it utilized?

97 MR. YAMAUCHI:

When we need to do amplifications, we go wherever.

98 MR. HARMON:

Is that the only function for those rooms?

99 MR. YAMAUCHI:

Basically, yes.

100 MR. SCHECK:

Objection. Leading.

101 THE COURT:

Overruled.

102 MR. HARMON:

Basically, yes?

103 MR. YAMAUCHI:

Yes.

104 MR. HARMON:

Is it--do you know whether or not it's routinely kept locked?

105 MR. SCHECK:

Objection. Leading.

106 THE COURT:

Overruled.

107 MR. YAMAUCHI:

Yes, it is.

108 MR. HARMON:

And where do you obtain the key?

109 MR. YAMAUCHI:

Well, I have a key and Erin Riley does and Harry Klan because we work in that area. I believe some supervisors do too.

110 MR. HARMON:

I'm not sure--Harry Klan, that's a new name we haven't mentioned yet. Who is he?

111 MR. YAMAUCHI:

I'm sorry. He's the other DNA analyst that we have.

112 MR. HARMON:

Okay. Do you recall about what time it was--or strike that. Let's just talk generally. You get over to the--you got your key to the amplification area, Parker Center. Will you describe what's shown in the photograph--on the left-hand side, it's labeled, "Pre-amplification." What are you doing there?

113 MR. YAMAUCHI:

This is a room that's separated from the amplification room. Amplification room is the one with the instrument thermocycler and this--in the pre-amplification area is where we set the tubes up, process them with the right chemicals to be taken over and placed into the machine.

114 MR. HARMON:

How many different rooms are there in the amplification area at Parker Center?

115 MR. YAMAUCHI:

We have one two three, four rooms in that area.

116 MR. HARMON:

And you've described the pre-amplification--is that the same room as the amplification takes place?

117 MR. YAMAUCHI:

No, it's not.

118 MR. HARMON:

Okay. So the photo in the left-hand side shows what you've just described, and that's in one room, and then the next photo, it's labeled "Amplification," what's going on in that photograph?

119 MR. YAMAUCHI:

That's where the actual amplification process takes place. That's where the thermal cycler machine is housed, in that room.

120 MR. HARMON:

And at this point in the process, are there additional controls that are added to the controls that you've described in the extraction process?

121 MR. YAMAUCHI:

Well, those would be set up over here, but yes, there are. For the amplification process, we have another positive and negative control.

122 MR. HARMON:

And what is their function?

123 MR. YAMAUCHI:

Well, like I was saying, before you have the controls that we take at the scene, we've got controls at that extraction point. We also have another set of controls at this point where we're going to run the amplification just to give us more information again.

124 MR. HARMON:

What's shown in the next photo on the right, the hibridization--the one that's labeled "Hybridization," what are you doing there?

125 MR. YAMAUCHI:

That's to display the hybridization strips that we have, and those are the strips that contained the probes that we eventually get our results from.

126 MR. HARMON:

Okay. This is all the commercially available product?

127 MR. YAMAUCHI:

Yes, it is.

128 MR. HARMON:

Okay. And photograph 3--what does that photograph on the right-hand side show?

129 MR. YAMAUCHI:

Okay. At Parker Center, after we do the strips, we've got to photograph them, and that's the area over there at Parker Center that we do that.

130 MR. HARMON:

What are you actually taking photographs of?

131 MR. YAMAUCHI:

The strips themselves.

132 MR. HARMON:

Okay. Then what do you do with the strips?

133 MR. YAMAUCHI:

We throw the strips away after we're done.

KEY QUOTE
134 MR. HARMON:

Why is that?

135 MR. YAMAUCHI:

Because the strips themselves, they tend to discolor. They won't be as good as that original photograph if you hold on to them. So we have no reason to keep them.

136 MR. HARMON:

At this point, generally speaking, as you do the procedure in Los Angeles Police Department, you've got photographs of the strips, and the board has another line entitled "Piper tech electrophoresis." Can you describe what's in the left-hand photo, picture of those doors?

137 MR. YAMAUCHI:

That's the room at piper tech where we perform the product gels.

138 MR. HARMON:

What is the name of that room?

139 MR. YAMAUCHI:

Instrument room.

140 MR. HARMON:

And where is that in relation to serology?

141 MR. YAMAUCHI:

It would be separated from it by a wall, but kind of like right next to it.

142 MR. HARMON:

Adjacent to one another?

143 MR. YAMAUCHI:

Yes.

144 MR. HARMON:

But separate rooms?

145 MR. YAMAUCHI:

Yes.

146 MR. HARMON:

And is there some sort of security device that monitors people coming in and out of the instrument room?

147 MR. YAMAUCHI:

Yes. We also have to use those access cards for that.

148 MR. HARMON:

Now, what do you need to take from the Parker Center at the end of the amplification and hybridization back to piper tech to take into the instrument room? What are you actually taking back there?

149 MR. YAMAUCHI:

Have to take some of the amplified product from this--this reagent that's held in the thermal cycler, and that has to be brought back to piper tech to be analyzed in this product gel.

150 MR. HARMON:

And what's the purpose of the product gel?

151 MR. YAMAUCHI:

It's the kind to tell you whether or not the amplification process took place, and it can also give you more information as to a relative idea how much DNA was formed by the amplification although that's not real accurate.

152 MR. HARMON:

A little while ago, you mentioned that it was important to avoid PCR product carry-over to keep the amplification separate from other areas.

153 MR. SCHECK:

Objection. Leading.

154 MR. HARMON:

It's foundation.

155 THE COURT:

Overruled.

156 MR. HARMON:

Do you recall discussing that a little while ago?

157 MR. YAMAUCHI:

Yes.

158 MR. HARMON:

Does bringing the PCR product back into the instrument room violate that?

159 MR. SCHECK:

Objection. Leading.

160 THE COURT:

Overruled.

161 MR. YAMAUCHI:

No. The reason we have it in the instrument room is because it's separated physically from serology where we do our extractions.

162 MR. HARMON:

Are you familiar with other laboratories where all of these functions are done within the same building, but in different rooms?

163 MR. SCHECK:

Objection. Leading.

164 THE COURT:

Overruled.

165 MR. YAMAUCHI:

That sounds reasonable, yes.

166 MR. HARMON:

What do you end up with at the end of the product gel electrophoresis?

167 MR. YAMAUCHI:

You wind up with electrophoresis gel where the product is moved through the electrical field and so it can be visualized and noted.

168 MR. HARMON:

Okay. We can take the board down. Do you want to have a seat again?

169 MR. SCHECK:

Your Honor, before the board goes down, could we ask the witness about position?

170 MR. HARMON:

Now, this board doesn't actually reflect everything in the same position and location as it was when you performed your tests on June 14th and June 15th, does it?

171 MR. YAMAUCHI:

Well, this--this work area right here (Indicating)--

172 MR. HARMON:

The product gel?

173 MR. YAMAUCHI:

--was changed. We were on a bench area that was kind of around the corner from that at the time that I actually analyzed evidence in the Simpson case. But since then, we've had to move our stuff over to the other corner.

174 MR. HARMON:

Same room?

175 MR. YAMAUCHI:

Yes. Same room.

176 MR. HARMON:

How many feet apart?

177 MR. YAMAUCHI:

Oh, 10, 15 feet or so.

178 MR. HARMON:

Okay.

179 THE COURT:

Same equipment?

180 MR. YAMAUCHI:

Yes. Equipment is the same.

181 MR. HARMON:

Okay. You can have a seat again, Mr. Yamauchi.

182 (The witness complies.)
183 MR. HARMON:

Now, you've described the samples that you extract--that you sampled and that you extracted. Did you subject them to the PCR DQ-Alpha testing process in the manner that--in the general manner and sequence that is shown on the exhibit 281, the photo display board?

184 MR. YAMAUCHI:

Yes.

185 MR. HARMON:

Okay. And if you can, I would like you to break down the process and ask about how long each step took, if that's possible to do. For example, how long did the chelex extraction process take you on June 14th for the samples that you've described to this jury?

186 MR. YAMAUCHI:

As in any case, for example, or situation, it's about an hour and a half.

187 MR. HARMON:

Okay. And then from the extraction process, did you go right over to Parker Center after that?

188 MR. SCHECK:

Objection. Leading.

189 THE COURT:

Overruled.

190 MR. YAMAUCHI:

Well, I don't know when I had my lunch that day, but that would have been the next step. Eventually, I would have had to drive over there.

KEY QUOTE
191 MR. HARMON:

And you process them, amplification, hybridization and photography, in the manner that's shown on the photo board 281 for identification?

192 MR. SCHECK:

Objection. Asked and answered.

193 THE COURT:

Overruled.

194 MR. YAMAUCHI:

Yes.

195 MR. HARMON:

Okay. And did you obtain PCR DQ-Alpha results on samples that are in the list of samples that you've previously described to the jury?

196 MR. YAMAUCHI:

Yes. I analyzed those samples.

197 MR. HARMON:

Okay.

Temperature

procedural

Key Quotes (4)

Collin Yamauchi
Mostly because when you're walking along around the police station, it makes the detectives and people over there kind of nervous if they see little test-tube things. So I just want to make sure it's covered up.
Explaining why he wrapped sample tubes in a chem-wipe for transport — an unexpectedly casual and humanizing moment in otherwise dry technical testimony.
Collin Yamauchi
We throw the strips away after we're done. Because the strips themselves, they tend to discolor. They won't be as good as that original photograph if you hold on to them. So we have no reason to keep them.
Disclosure that physical hybridization strips were destroyed after photography — a detail the defense could later exploit regarding evidence preservation.
Barry Scheck
He asked the same question. He always does that.
A rare speaking objection from Scheck, revealing his frustration with Harmon's repeated leading questions and earning a rebuke from Judge Ito.
Collin Yamauchi
I don't know when I had my lunch that day, but that would have been the next step. Eventually, I would have had to drive over there.
A candid, slightly deflating answer when pressed about the exact sequence and timing on June 14th — illustrates the limits of his specific recollection of the day.

Evidence (1)

People's 281
LAPD PCR typing display board — a photo board showing the full PCR DQ-Alpha process across Piper Tech extraction, Parker Center amplification/hybridization, and Piper Tech electrophoresis
introduced and used by witness during step-down demonstration

Notable Exchanges (2)

Barry ScheckLance A. Ito
After Scheck's speaking objection ('He asked the same question. He always does that.'), Ito warned him about speaking objections and Scheck apologized.
tense
Lance A. ItoCollin Yamauchi
Judge Ito independently asked the witness whether the equipment in the relocated product gel area was the same as during the Simpson case testing — a rare judicial interjection.
neutral/clarifying

Light Moments (1)

Collin Yamauchi
Yamauchi explained that he wrapped sample tubes in a chem-wipe for transport through the police station because seeing 'little test-tube things' makes detectives nervous.

Witness Demeanor

(The witness complies.) — steps down for board demonstration and returns to seat

Objections

14 objections (2 sustained, 12 overruled)
Proceeding 6172 • 197 utterances • Prosecution witness
Criminal Trial
Department 103
⚖️ Start
📂 MAY 24, 1995 📄 Direct examination of Collin Y
MAY 24, 1995 KRT DvH TD